基蛋生物(603387.SH):擬斥3000萬元投設全資子公司 開展分子診斷與基因檢測業務
格隆匯1月3日丨基蛋生物(603387.SH)公佈,公司根據業務發展實際需要,為完善公司整體佈局,進一步落實公司在分子診斷與基因檢測板塊的戰略發展規劃,以及更好的激發研發團隊的創新活力,公司擬使用自有資金3000萬元人民幣投資設立全資子公司江蘇新序生物科技有限公司(暫定名,名稱以最終核准登記為準)。該子公司將開展分子診斷與基因檢測相關儀器、試劑、耗材的研發、生產和銷售業務。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.